The rationale for continuous dopaminergic stimulation in advanced Parkinson's disease

Parkinsonism and Related Disorders

Volumn 13, Issue SUPPL. SEPT., 2007, Pages

  Nyholm, Dag ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Continuous dopaminergic stimulation; Dopaminergic loss; Motor complications; Oral levodopa; Parkinson's disease

Indexed keywords

APOMORPHINE; LEVODOPA;

ARTICLE; BASAL GANGLION; BRAIN DEGENERATION; BRAIN NERVE CELL; CONTINUOUS DOPAMINERGIC STIMULATION; DISEASE SEVERITY; DOPAMINE RELEASE; DYSKINESIA; HUMAN; MOTOR CONTROL; MOTOR DYSFUNCTION; NERVE CELL DEGENERATION; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; THERAPY;

DISEASE PROGRESSION; DOPAMINE; DOPAMINE AGONISTS; HUMANS; PARKINSON DISEASE;

EID: 34548819330     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2007.06.005     Document Type: Article

References (44)

1. Alexander G.E., and Crutcher M.D. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci 13 7 (1990) 266-271
2. Obeso J.A., Rodriguez-Oroz M.C., Rodriguez M., Arbizu J., and Gimenez-Amaya J.M. The basal ganglia and disorders of movement: pathophysiological mechanisms. News Physiol Sci 17 (2002) 51-55
3. Olanow C.W., Obeso J.A., and Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 5 8 (2006) 677-687
4. Miyasaki J.M., Martin W., Suchowersky O., Weiner W.J., and Lang A.E. Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 58 1 (2002) 11-17
5. Pahwa R., Factor S.A., Lyons K.E., Ondo W.G., Gronseth G., Bronte-Stewart H., et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66 7 (2006) 983-995
6. Nutt J.G., and Holford N.H. The response to levodopa in Parkinson's disease: imposing pharmacological law and order. Ann Neurol 39 5 (1996) 561-573
7. Lieberman A., Olanow C.W., Sethi K., Swanson P., Waters C.H., Fahn S., et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study Group. Neurology 51 4 (1998) 1057-1062
8. Bracco F., Battaglia A., Chouza C., Dupont E., Gershanik O., Marti Masso J.F., et al. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study. CNS Drugs 18 11 (2004) 733-746
9. Rascol O., Brooks D.J., Melamed E., Oertel W., Poewe W., Stocchi F., et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 365 9463 (2005) 947-954
10. Rinne U.K., Larsen J.P., Siden A., and Worm-Petersen J. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology 51 5 (1998) 1309-1314
11. Onn S.P., West A.R., and Grace A.A. Dopamine-mediated regulation of striatal neuronal and network interactions. Trends Neurosci 23 10 Suppl. (2000) S48-S56
12. Walters J.R., Ruskin D.N., Allers K.A., and Bergstrom D.A. Pre- and postsynaptic aspects of dopamine-mediated transmission. Trends Neurosci 23 10 Suppl. (2000) S41-S47
13. West A.R., and Grace A.A. Opposite influences of endogenous dopamine D1 and D2 receptor activation on activity states and electrophysiological properties of striatal neurons: studies combining in vivo intracellular recordings and reverse microdialysis. J Neurosci 22 1 (2002) 294-304
14. Crossman A.R. Functional anatomy of movement disorders. J Anat 196 Pt. 4 (2000) 519-525
15. Grace A.A., and Bunney B.S. The control of firing pattern in nigral dopamine neurons: single spike firing. J Neurosci 4 11 (1984) 2866-2876
16. DeLong M.R., Crutcher M.D., and Georgopoulos A.P. Relations between movement and single cell discharge in the substantia nigra of the behaving monkey. J Neurosci 3 8 (1983) 1599-1606
17. Suri R.E. TD models of reward predictive responses in dopamine neurons. Neural Netw 15 4-6 (2002) 523-533
18. Schultz W. Predictive reward signal of dopamine neurons. J Neurophysiol 80 1 (1998) 1-27
19. Albin R.L., Young A.B., and Penney J.B. The functional anatomy of disorders of the basal ganglia. Trends Neurosci 18 2 (1995) 63-64
20. Agid Y. Parkinson's disease: pathophysiology. Lancet 337 8753 (1991) 1321-1324
21. Obeso J.A., Rodriguez-Oroz M., Marin C., Alonso F., Zamarbide I., Lanciego J.L., et al. The origin of motor fluctuations in Parkinson's disease: importance of dopaminergic innervation and basal ganglia circuits. Neurology 62 1 Suppl. 1 (2004) S17-S30
22. Obeso J.A., Rodriguez-Oroz M.C., Rodriguez M., Lanciego J.L., Artieda J., Gonzalo N., et al. Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci 23 10 Suppl. (2000) S8-S19
23. Burch D., and Sheerin F. Parkinson's disease. Lancet 365 9459 (2005) 622-627
24. Chase T.N., and Oh J.D. Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications. Ann Neurol 47 4 Suppl. 1 (2000) S122-S129
25. Melamed E., Hefti F., and Wurtman R.J. Nonaminergic striatal neurons convert exogenous l-dopa to dopamine in parkinsonism. Ann Neurol 8 6 (1980) 558-563
26. Nutt J.G. Motor fluctuations and dyskinesia in Parkinson's disease. Parkinsonism Relat Disord 8 2 (2001) 101-108
27. Calon F., Morissette M., Rajput A.H., Hornykiewicz O., Bedard P.J., and Di P.T. Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications. Mov Disord 18 3 (2003) 241-253
28. Chan P.L., Nutt J.G., and Holford N.H. Pharmacokinetic and pharmacodynamic changes during the first four years of levodopa treatment in Parkinson's disease. J Pharmacokinet Pharmacodyn 32 3/4 (2005) 459-484
29. Chase T.N., and Oh J.D. Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism. Trends Neurosci 23 10 Suppl. (2000) S86-S91
30. Oh J.D., and Chase T.N. Glutamate-mediated striatal dysregulation and the pathogenesis of motor response complications in Parkinson's disease. Amino Acids 23 1-3 (2002) 133-139
31. Fahn S. The spectrum of levodopa-induced dyskinesias. Ann Neurol 47 4 Suppl. 1 (2000) S2-S9
32. Bezard E., Brotchie J.M., and Gross C.E. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci 2 8 (2001) 577-588
33. Marsden C.D., and Parkes J.D. "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet 1 7954 (1976) 292-296
34. Olanow C.W., Agid Y., Mizuno Y., Albanese A., Bonuccelli U., Damier P., et al. Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord 19 9 (2004) 997-1005
35. Rascol O., Brooks D.J., Korczyn A.D., De Deyn P.P., Clarke C.E., and Lang A.E. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 342 20 (2000) 1484-1491
36. Nutt J.G. Continuous dopaminergic stimulation: is it the answer to the motor complications of levodopa?. Mov Disord (2006)
37. Nutt J.G., Obeso J.A., and Stocchi F. Continuous dopamine-receptor stimulation in advanced Parkinson's disease. Trends Neurosci 23 10 Suppl. (2000) S109-S115
38. Olanow C.W., Obeso J.A., and Stocchi F. Drug insight: continuous dopaminergic stimulation in the treatment of Parkinson's disease. Nat Clin Pract Neurol 2 7 (2006) 382-392
39. Blanchet P.J., Calon F., Martel J.C., Bedard P.J., Di P.T., Walters R.R., et al. Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys. J Pharmacol Exp Ther 272 2 (1995) 854-859
40. Bibbiani F., Costantini L.C., Patel R., and Chase T.N. Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates. Exp Neurol 192 1 (2005) 73-78
41. Deleu D., Hanssens Y., and Northway M.G. Subcutaneous apomorphine: an evidence-based review of its use in Parkinson's disease. Drugs Aging 21 11 (2004) 687-709
42. Nilsson D., Nyholm D., and Aquilonius S.M. Duodenal levodopa infusion in Parkinson's disease-long-term experience. Acta Neurol Scand 104 6 (2001) 343-348
43. Nyholm D., Nilsson Remahl A.I., Dizdar N., Constantinescu R., Holmberg B., Jansson R., et al. Duodenal levodopa infusion monotherapy vs. oral polypharmacy in advanced Parkinson disease. Neurology 64 2 (2005) 216-223
44. Stocchi F., Ruggieri S., Vacca L., and Olanow C.W. Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease. Brain 125 Pt. 9 (2002) 2058-2066